UPDATE: Incyte (INCY) Tops Q3 EPS by 12c, Beats on Revenues; Boosts FY17 Jakafi Net Product Revenue Guidance

Incyte (NASDAQ: INCY) reported Q3 EPS of $0.17, $0.12 better than the analyst estimate of $0.05. Revenue for the quarter came in at $381.53 million versus the consensus estimate of $359.7 million.

• $304 million of 2017 third-quarter net product revenues from Jakafi® (ruxolitinib), representing 36 percent growth over the same period last year
• Progress across the portfolio as multiple candidates enter late-stage development trials
• Two recent collaborations further expand potential and scope of Incyte’s combination immunotherapy development activities

For earnings history and earnings-related data on Incyte (INCY) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Diana Shipping drops bid for Genco after price demands spike to $36.91
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c